Merck, Keytruda
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with asbestos.
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...
FDA Approves Keytruda Plus Chemo for Pleural Mesothelioma Subset
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial.
FDA approves MSD’s KEYTRUDA as first-line MPM treatment
The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.
Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM
Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024,
FiercePharma8h
Ahead of adcomm, FDA challenges broad use of PD-1 drugs in stomach cancer patients
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...
MedPage Today6h
Immunotherapy May Not Benefit All Gastroesophageal Cancer Patients, FDA Staff Says
"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...
STAT7d
FDA formalizes protocol for international cancer trials
The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...
BioSpace6d
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has Something to Prove
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
FiercePharma4d
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
MarketWatch6d
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
ThePrint on MSN4d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...